MolDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test

Envisia Genomic Classifier is covered for patients with ILD suspected of idiopathic pulmonary fibrosis when HRCT does not show a definitive UIP pattern and no other cause of ILD is identified; testing must be performed on bronchoscopy transbronchial biopsy tissue and interpreted with clinical and radiographic data. Coverage is limited to this diagnostic scenario to help avoid higher-risk surgical lung biopsy and is not provided for patients with definitive HRCT UIP or identified non-idiopathic causes of ILD.

"Envisia Genomic Classifier is covered for patients with interstitial lung disease (ILD) who are suspected of idiopathic pulmonary fibrosis (IPF) and who do not have a definitive usual interstitial ..."

Sign up to see full coverage criteria, indications, and limitations.